Pacific Biosciences of California (NASDAQ:PACB) Stock Price Down 8.6%
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Down 8.6%
Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Rating)'s stock price dropped 8.6% during mid-day trading on Tuesday . The company traded as low as $6.23 and last traded at $6.35. Approximately 56,064 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 5,694,436 shares. The stock had previously closed at $6.95.
美國加州太平洋生物科技公司(納斯達克代碼：PACB-GET Rating)週二午盤股價下跌8.6%，最低報6.23美元，尾盤報6.35美元。午盤，約56,064股股票易手，較日均成交量5,694,436股下跌99%。該股此前收盤報6.95美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
PACB has been the subject of a number of research analyst reports. Canaccord Genuity Group decreased their target price on Pacific Biosciences of California from $17.00 to $14.00 and set a "buy" rating for the company in a research note on Friday, August 5th. Piper Sandler decreased their target price on Pacific Biosciences of California from $7.50 to $6.00 in a research note on Sunday, August 21st. Finally, Cowen reduced their price objective on Pacific Biosciences of California to $8.00 in a research report on Tuesday, August 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Pacific Biosciences of California presently has an average rating of "Moderate Buy" and an average price target of $22.00.
PACB已經成為許多研究分析師報告的主題。Cancord Genuity Group在8月5日(星期五)的一份研究報告中將其對加州太平洋生物科學公司的目標價從17.00美元下調至14.00美元，並對該公司設定了“買入”評級。派珀·桑德勒在8月21日週日的一份研究報告中將他們對加州太平洋生物科學公司的目標價從7.50美元下調至6.00美元。最後，考恩在8月9日星期二的一份研究報告中將他們對加州太平洋生物科學公司的目標價格下調至8.00美元。一位分析師對該股的評級為賣出，一位分析師給出了持有評級，四位分析師給出了買入評級。根據MarketBeat的數據，加州太平洋生物科學公司目前的平均評級為“中等買入”，平均目標價為22.00美元。
Pacific Biosciences of California Stock Down 0.2 %
加州太平洋生物科學公司股價下跌0.2%
The firm has a market cap of $1.38 billion, a P/E ratio of -6.66 and a beta of 1.33. The company has a quick ratio of 11.07, a current ratio of 11.50 and a debt-to-equity ratio of 1.31. The firm has a fifty day moving average of $5.78 and a 200-day moving average of $6.68.
該公司的市值為13.8億美元，市盈率為-6.66，貝塔係數為1.33。該公司的速動比率為11.07，流動比率為11.50，債務權益比為1.31。該公司的50日移動均線切入位在5.78美元，200日移動均線切入位在6.68美元。
Institutional Trading of Pacific Biosciences of California
加州太平洋生物科學公司的機構交易
Several institutional investors and hedge funds have recently bought and sold shares of PACB. Advisor Group Holdings Inc. raised its stake in Pacific Biosciences of California by 71.4% in the fourth quarter. Advisor Group Holdings Inc. now owns 14,522 shares of the biotechnology company's stock valued at $299,000 after buying an additional 6,050 shares during the period. Envestnet Asset Management Inc. bought a new stake in Pacific Biosciences of California in the fourth quarter valued at approximately $410,000. Bank of America Corp DE raised its stake in Pacific Biosciences of California by 75.5% in the fourth quarter. Bank of America Corp DE now owns 455,984 shares of the biotechnology company's stock valued at $9,330,000 after buying an additional 196,212 shares during the period. HighTower Advisors LLC raised its stake in Pacific Biosciences of California by 11.9% in the fourth quarter. HighTower Advisors LLC now owns 90,885 shares of the biotechnology company's stock valued at $1,862,000 after buying an additional 9,646 shares during the period. Finally, Teacher Retirement System of Texas raised its stake in Pacific Biosciences of California by 25.2% in the fourth quarter. Teacher Retirement System of Texas now owns 37,011 shares of the biotechnology company's stock valued at $757,000 after buying an additional 7,450 shares during the period.
幾家機構投資者和對衝基金最近買賣了PACB的股票。Advisor Group Holdings Inc.在第四季度增持了加州太平洋生物科學公司的股份71.4%。Advisor Group Holdings Inc.現在持有這家生物技術公司14,522股股票，價值29.9萬美元，在此期間又購買了6,050股。Envestnet Asset Management Inc.在第四季度購買了加州太平洋生物科學公司的新股份，價值約41萬美元。第四季度，美國銀行(Bank Of America Corp DE)將其在加州太平洋生物科學公司的持股比例提高了75.5%。美國銀行DE現在擁有455,984股生物技術公司的股票，價值9,330,000美元，在此期間又購買了196,212股。HighTower Advisors LLC在第四季度將其在加州太平洋生物科學公司的持股增加了11.9%。HighTower Advisors LLC現在持有這家生物技術公司90,885股股票，價值1,862,000美元，在此期間又購買了9,646股。最後，德克薩斯州教師退休系統在第四季度將其在加州太平洋生物科學公司的持股比例提高了25.2%。德克薩斯州的教師退休系統現在擁有37,011股這家生物技術公司的股票，價值757,000美元，在此期間又購買了7,450股。
Pacific Biosciences of California Company Profile
加州太平洋生物科學公司簡介
(Get Rating)
(獲取評級)
Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.
加州太平洋生物科學公司設計、開發和製造測序系統，以解決基因複雜的問題。該公司提供進行、監測和分析生化測序反應的PacBio系統；消耗品，包括單分子實時(SMRT)細胞；以及為特定工作流程設計的各種試劑盒，如將DNA轉化為SMRTbell雙鏈DNA文庫格式的模板製備試劑盒，包括連接酶、緩衝液和核酸外切酶等分子生物學試劑。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Pacific Biosciences of California (PACB)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
- 免費獲取StockNews.com關於加州太平洋生物科學的研究報告(PACB)
- 這家醫療設備製造商準備好繼續反彈了嗎？
- 第三季度財報公佈前最值得關注的五(5)只股票
- Take-Two Interactive是否已經退化為一招小馬？
- 具有有趣內幕活動的四隻廉價股票
- 隨着收購傳言的甚囂塵上，Lyft能否成功？
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《加州日報》太平洋生物科學的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對加利福尼亞州太平洋生物科學公司和相關公司的最新新聞和分析師評級的每日簡要摘要。